Targeting the “Undruggable”: Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy
Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 2058-2088
DOI: 10.1021/acs.jmedchem.4c00526 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.02.2025. Verfasst von Tiantian Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, P. R. China. Hauptthemen laut MEDLINE: Proliferating Cell Nuclear Antigen, Neoplasms, Antineoplastic Agents, Small Molecule Libraries. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 276 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangxi University of Traditional Chinese Medicine, Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
PCNA plays multiple roles in cancer development, including cell proliferation regulation, DNA repair, replication, and serving as a widely used biomarker and therapeutic target. Despite its significant role in oncology, PCNA has historically been considered "undruggable" due to the absence of known endogenous small molecule modulators and identifiable ligand binding sites. Unlike other protein-protein interfaces, PCNA lacks explicit binding grooves, featuring a relatively small and shallow surface pocket, which hinders the discovery of traditional small molecule targets. Recent breakthroughs have introduced promising PCNA-targeting candidates, with ATX-101 and AOH1996 entering phase I clinical trials for cancer therapy, garnering academic and industry interest. These achievements provide new evidence for PCNA as a drug target. This article provides insight and perspective on the application of small-molecule PCNA inhibitors in cancer treatment, covering PCNA function, its relationship with cancer, structural modification of small molecule inhibitors, and discovery strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, P. R. China.
- National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, P. R. China.
- Jiangxi Provincial Key Laboratory of TCM Female Reproductive Health and Related Diseases Research and Transformation, Jiangxi University of Chinese Medicine, Nanchang 330004, P. R. China.
ORCID-Profile: Zengtao Wang
Förderung
- National Natural Science Foundation of China
- Jiangxi University of Traditional Chinese Medicine
- Natural Science Foundation of Jiangxi Province
Zitieren
APA
Wang, T., & Wang, Z. (2025). Targeting the “Undruggable”: Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy. Journal of Medicinal Chemistry, 68(3), 2058-2088. https://doi.org/10.1021/acs.jmedchem.4c00526
Vancouver
Wang T, Wang Z. Targeting the “Undruggable”: Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy. Journal of Medicinal Chemistry. 2025;68(3):2058-2088. doi:10.1021/acs.jmedchem.4c00526
BibTeX
@article{Wang2025,
author = {Wang, Tiantian and Wang, Zengtao},
title = {Targeting the “Undruggable”: Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {3},
pages = {2058--2088},
doi = {10.1021/acs.jmedchem.4c00526}
}
EUVIMED